Goldman Sachs Group Inc Y M Abs Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

  • $596 Billion
  • Q1 2025

A detailed history of Goldman Sachs Group Inc transactions in Y M Abs Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 201,776 shares of YMAB stock, worth $889,832. This represents 0.0% of its overall portfolio holdings.

Number of Shares
201,776
Previous 201,776 -0.0%
Holding current value
$889,832
Previous $893,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 09, 2025
SELL
$4.43 - $8.17 $77,077 - $142,149
-17,399 Reduced 7.94%
201,776 $893,000
Q4 2024

Feb 11, 2025
SELL
$7.76 - $15.69 $26,578 - $53,738
-3,425 Reduced 1.54%
219,175 $1.72 Million
Q3 2024

Nov 14, 2024
BUY
$9.95 - $15.39 $834,416 - $1.29 Million
83,861 Added 60.45%
222,600 $2.92 Million
Q2 2024

Aug 13, 2024
SELL
$11.6 - $17.25 $2.63 Million - $3.91 Million
-226,797 Reduced 62.05%
138,739 $1.68 Million
Q1 2024

May 15, 2024
SELL
$6.57 - $18.69 $212,966 - $605,836
-32,415 Reduced 8.15%
365,536 $5.94 Million
Q4 2023

Feb 13, 2024
BUY
$4.88 - $7.42 $41,987 - $63,841
8,604 Added 2.21%
397,951 $2.71 Million
Q3 2023

May 14, 2024
SELL
$4.86 - $7.23 $41,815 - $62,206
-8,604 Reduced 2.16%
389,347 $2.12 Million
Q3 2023

Nov 14, 2023
SELL
$4.86 - $7.23 $64,657 - $96,187
-13,304 Reduced 3.3%
389,347 $2.12 Million
Q2 2023

May 14, 2024
BUY
$5.68 - $10.34 $1.2 Million - $2.19 Million
211,860 Added 111.04%
402,651 $2.73 Million
Q2 2023

Aug 14, 2023
BUY
$5.68 - $10.34 $1.2 Million - $2.19 Million
211,860 Added 111.04%
402,651 $2.73 Million
Q1 2023

May 14, 2024
SELL
$2.83 - $5.11 $356,752 - $644,171
-126,061 Reduced 39.79%
190,791 $955,000
Q1 2023

May 11, 2023
SELL
$2.83 - $5.11 $356,752 - $644,171
-126,061 Reduced 39.79%
190,791 $955,000
Q4 2022

May 14, 2024
BUY
$3.0 - $15.17 $401,325 - $2.03 Million
133,775 Added 73.07%
316,852 $1.55 Million
Q4 2022

Feb 13, 2023
BUY
$3.0 - $15.17 $401,325 - $2.03 Million
133,775 Added 73.07%
316,852 $1.55 Million
Q3 2022

May 14, 2024
BUY
$13.96 - $19.67 $437,659 - $616,674
31,351 Added 20.66%
183,077 $2.64 Million
Q3 2022

Nov 10, 2022
BUY
$13.96 - $19.67 $437,659 - $616,674
31,351 Added 20.66%
183,077 $2.64 Million
Q2 2022

May 14, 2024
SELL
$8.22 - $15.13 $2.02 Million - $3.73 Million
-246,225 Reduced 61.87%
151,726 $2.3 Million
Q2 2022

Aug 15, 2022
BUY
$8.22 - $15.13 $210,555 - $387,554
25,615 Added 20.31%
151,726 $2.3 Million
Q1 2022

May 16, 2022
SELL
$6.55 - $17.42 $597,687 - $1.59 Million
-91,250 Reduced 41.98%
126,111 $1.5 Million
Q4 2021

Feb 14, 2022
SELL
$15.51 - $29.31 $9.24 Million - $17.5 Million
-595,994 Reduced 73.28%
217,361 $3.52 Million
Q3 2021

Nov 10, 2021
BUY
$27.47 - $37.31 $22.3 Million - $30.3 Million
813,355 New
813,355 $23.2 Million

Others Institutions Holding YMAB

# of Institutions
105
Shares Held
27.1M
Call Options Held
38.4K
Put Options Held
2.1K
View Full List

About Y-mAbs Therapeutics, Inc.

YMAB Quotes by TradingView
  • Ticker YMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,719,500
  • Market Cap $193M
  • Description
  • Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...
More about YMAB
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email